

## **United States Blood Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)**

Market Report | 2025-04-28 | 70 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

The United States Blood Glucose Monitoring Market size is estimated at USD 16.09 billion in 2025, and is expected to reach USD 29.65 billion by 2030, at a CAGR of 13% during the forecast period (2025-2030).

Diabetic patients were at a higher risk of hospitalizations and complications during the COVID-19 pandemic due to hyper- or hypoglycemia, metabolic comorbidities, and a more severe SARS-CoV-2 infection. The maintenance of euglycemia was important to decrease both morbidity and mortality in the hospital setting. According to experts, inpatient use of diabetes technology in patients with proper institutional protocols was safe, improved inpatient glycemic outcomes, and played a vital role in managing hypoglycemia and hyperglycemia in hospitalized patients.

Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. Blood glucose measurement helps find out how well blood glucose is being used and how well glucose is being controlled in the body. Over time, the readings provide the patient and their health professionals with the information required to determine the best management strategy for diabetes. When blood glucose levels are too high or too low, they can be managed successfully, which keeps health problems related to diabetes to a minimum.

According to the National Center for Health Statistics, approximately 32.8% of adults aged 18 and over in the United States will be obese in 2021. In obese individuals, the fat cells in the body release pro-inflammatory chemicals, which may make the body less sensitive to the insulin it produces by disrupting the function of insulin-responsive cells. Thus, these individuals need external insulin shots and are obligated to use a blood glucose monitoring device, such as a glucometer.

Technological advancements in blood glucose meters, including cellular-connected devices that automatically upload SMBG data

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

to secure cloud-based databases, allow for improved sharing and monitoring of SMBG data. Real-time monitoring of SMBG data presents opportunities to provide timely support to patients who are responsive to abnormal SMBG recordings. Such diabetes remote monitoring programs can give people with T2D who don't have it well under control the extra help they need to improve critical outcomes, which will help the market in the years to come.

## US Blood Glucose Monitoring Market Trends

### Rising Diabetes Prevalence in the United States

In the United States, the number of people with diabetes has gone up a lot in the last 20 years. This is due to the rise in obesity and changes in lifestyle due to less physical activity, unhealthy eating habits, and other things.

The CDC National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type 2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.

The ADA, the Endocrine Society, the American College of Physicians, the American Academy of Pediatrics, the Society of General Internal Medicine, and the National Academy of Medicine published statements and issued calls to action to address SDOH at the individual, organizational, and policy levels. In 2021, the ADA also published a scientific review describing the associations between SDOH and diabetes risk and outcomes, focusing on socioeconomic status, health literacy, the food environment, food insecurity, and neighborhood and physical environments, among other topics.

In the United States, there are several innovations in diabetes management platforms by startups, like Glooko, OneDrop, Verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, and Orgenesis, which have launched in the market. The growing awareness among people regarding advanced diabetes devices is improving the adaptability of blood glucose monitoring devices. Leading manufacturers are focusing on technological innovations and developing advanced products to gain a substantial market share.

In May 2021, the World Health Assembly agreed on a resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin and promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes. In May 2022, the World Health Assembly endorsed five global diabetes coverage and treatment targets to be achieved by 2030.

Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.

### Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period

During the forecast period, the Continuous Glucose Monitoring segment is expected to register a CAGR of more than 19%.

Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxide, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.

CGMs help patients better control their glucose levels because they can see their glucose levels in real time without having to do a fingerstick. The use of a CGM can also eliminate the need for fingerstick blood glucose monitoring. The use of CGM by type-1

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

diabetic patients is very low as compared to type-2 diabetic patients. But the expenditure incurred by type-1 diabetic patients on these devices is nearly double that of type-2 diabetics. People with Type-2 diabetes don't use CGM as much as they could because they are expensive and it's not clear how well they work or if they even need to.

Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. In March 2022, Dexcom released G7 first in the U.K. and expanded the launch across Europe throughout 2022. The CGM system was under review by the Food and Drug Administration for an eventual U.S. release. The Dexcom G7 overcame many technical barriers, such as a short warm-up time, more accurate glucose readings, and a smaller size. Eversense E3 CGMs and other technological advances have made it much easier for doctors to treat diabetes and for patients to keep track of their blood sugar levels.

According to the Center for Health Care Strategies, for Medicaid agencies that can cover and increase access to CGMs for their beneficiaries and for the larger healthcare system, there is strong evidence that supports the benefits of CGM use for all people who are insulin-treated with an insulin pump or multiple daily insulin injections, and emerging evidence is showing the benefit of CGMs in patients on basal insulin.

The aforementioned factors are set to boost market growth.

## US Blood Glucose Monitoring Industry Overview

The United States Blood Glucose Monitoring Market is moderately fragmented, with few significant and generic players. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, have sent Dexcom ahead on its way in the race to create an artificial pancreas system rather than merely offering a boost to the continuous glucose monitoring devices market. There have been constant innovations driven by manufacturers such as Abbott and Medtronic while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

### **Table of Contents:**

#### 1 INTRODUCTION

##### 1.1 Study Assumptions and Market Definition

##### 1.2 Scope of the Study

#### 2 RESEARCH METHODOLOGY

#### 3 EXECUTIVE SUMMARY

#### 4 MARKET DYNAMICS

##### 4.1 Market Overview

##### 4.2 Drivers

##### 4.3 Restraints

##### 4.4 Porter's Five Forces Analysis

##### 4.4.1 Bargaining Power of Suppliers

##### 4.4.2 Bargaining Power of Consumers

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry

## 5 MARKET SEGMENTATION

- 5.1 Self-monitoring blood glucose devices (Value and Volume, 2017 - 2028)
  - 5.1.1 Glucometer Devices
  - 5.1.2 Test Strips
  - 5.1.3 Lancets
- 5.2 Continuous blood glucose monitoring devices (Value and Volume, 2017 - 2028)
  - 5.2.1 Sensors
  - 5.2.2 Durables (Receivers and Transmitters)

## 6 MARKET INDICATORS

- 6.1 Type-1 Diabetes population (2017 - 2028)
- 6.2 Type-2 Diabetes population (2017 - 2028)

## 7 COMPETITIVE LANDSCAPE

- 7.1 COMPANY PROFILES
  - 7.1.1 Abbott Diabetes Care
  - 7.1.2 Roche Holding AG
  - 7.1.3 LifeScan
  - 7.1.4 Dexcom Inc.
  - 7.1.5 Medtronic PLC
  - 7.1.6 Arkray Inc.
  - 7.1.7 Ascensia Diabetes Care
  - 7.1.8 Agamatrix Inc.
  - 7.1.9 Bionime Corporation
  - 7.1.10 Acon Laboratories Inc.
  - 7.1.11 Trivida Functional Medicine
  - 7.1.12 Rossmax International Ltd.
  - 7.1.13 Senseonics
- 7.2 COMPANY SHARE ANALYSIS
  - 7.2.1 Self-monitoring Blood Glucose Devices
    - 7.2.1.1 Abbott Diabetes Care
    - 7.2.1.2 Roche Holding AG
    - 7.2.1.3 Other Company Share Analyses
  - 7.2.2 Continuous Glucose Monitoring Devices
    - 7.2.2.1 Dexcom Inc.
    - 7.2.2.2 Medtronic PLC
    - 7.2.2.3 Abbott Diabetes Care
    - 7.2.2.4 Other Continuous Glucose Monitoring Devices

## 8 MARKET OPPORTUNITIES AND FUTURE TRENDS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**United States Blood Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)**

Market Report | 2025-04-28 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-27"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

